Vaccines

A new study reveals prior authorization policies cause critical delays for heart failure drugs, disproportionately harming vulnerable groups and raising safety concerns.

With a strong cash position and new leadership, Artiva pivots its AlloNK® cell therapy to autoimmune disease, targeting a pivotal trial for RA in 2026.

Biotech leader H. Martin Seidel joins Odyssey's SAB, a strategic move signaling accelerated development in the competitive autoimmune disease space.

An Alabama firm's key regulatory filing for a critical drug component could accelerate the development of cheaper cancer supportive care biosimilars.

After its Alzheimer's drug failed amidst controversy, Cassava Sciences rebrands as Filana Therapeutics, betting its future on a rare epilepsy disorder.

After facing intense local opposition, a critical materials firm scraps its Claiborne County plans but vows to find a new home within the state.

Agenus activates a key manufacturing pact with Zydus, scaling production for its promising BOT+BAL cancer therapy ahead of regulatory filings and market launch.

Eledon's tegoprubart gets Orphan Drug status, signaling a new era for liver transplant patients by potentially replacing toxic, decades-old therapies.

With its CAR-T therapy achieving franchise profitability and treating 10,000 patients, Legend Biotech eyes overall profit and next-gen cancer treatments.

Tenax Therapeutics achieves a major clinical trial goal, moving its promising drug TNX-103 closer to becoming the first approved therapy for a deadly heart condition.

Alzheon's pill ALZ-801 shows promise in early AD patients with high genetic risk, offering a potential path that avoids the brain swelling seen in IV drugs.

A global consortium pioneers new drugs designed specifically for children, moving away from harsh adult treatments for aggressive pediatric cancers.

OSE Immunotherapeutics confirms Marc Le Bozec as CEO, betting on his turnaround expertise to navigate market pressures and commercialize its key therapies.

A new line of ultra-pure proteins with endotoxin levels 10x below the standard could revolutionize advanced therapies and fix a key source of error in science.

After 15 years without new therapies, Tonix Pharma's TONMYA enters the fibromyalgia market with a unique sublingual drug and an ambitious commercial plan.

A new trial in China tests a dual-action antibody for esophageal cancer, a top killer. The therapy aims to unleash a two-pronged immune attack on tumors.

With $336M in the bank and three autoimmune drugs advancing, Jade Biosciences lays out a fast-paced timeline for key clinical milestones in 2026 and 2027.

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.